-
1
-
-
84895786240
-
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
-
Nooka AK, Kaufman JL, Muppidi S, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28(3):690-693.
-
(2014)
Leukemia
, vol.28
, Issue.3
, pp. 690-693
-
-
Nooka, A.K.1
Kaufman, J.L.2
Muppidi, S.3
-
3
-
-
20644460600
-
International staging system for multiple myeloma
-
Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.15
, pp. 3412-3420
-
-
Greipp, P.R.1
San Miguel, J.2
Durie, B.G.3
-
4
-
-
0016804136
-
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
-
Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-854.
-
(1975)
Cancer
, vol.36
, Issue.3
, pp. 842-854
-
-
Durie, B.G.1
Salmon, S.E.2
-
5
-
-
0032147210
-
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy
-
Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92(3):802-809.
-
(1998)
Blood
, vol.92
, Issue.3
, pp. 802-809
-
-
Drach, J.1
Ackermann, J.2
Fritz, E.3
-
6
-
-
84856706335
-
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: Analysis of patients treated in the MRC Myeloma IX trial
-
Boyd KD, Ross FM, Chiecchio L, et al; NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012;26(2):349-355.
-
(2012)
Leukemia
, vol.26
, Issue.2
, pp. 349-355
-
-
Boyd, K.D.1
Ross, F.M.2
Chiecchio, L.3
-
7
-
-
33847378314
-
Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myélome
-
Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109(8):3489-3495.
-
(2007)
Blood
, vol.109
, Issue.8
, pp. 3489-3495
-
-
Avet-Loiseau, H.1
Attal, M.2
Moreau, P.3
-
8
-
-
33750327901
-
Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma
-
Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034-2040.
-
(2006)
Leukemia
, vol.20
, Issue.11
, pp. 2034-2040
-
-
Fonseca, R.1
Van Wier, S.A.2
Chng, W.J.3
-
9
-
-
33748196399
-
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
-
Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006;108(5):1724-1732.
-
(2006)
Blood
, vol.108
, Issue.5
, pp. 1724-1732
-
-
Hanamura, I.1
Stewart, J.P.2
Huang, Y.3
-
10
-
-
27244445489
-
Molecular pathogenesis and a consequent classification of multiple myeloma
-
Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23(26):6333-6338.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.26
, pp. 6333-6338
-
-
Bergsagel, P.L.1
Kuehl, W.M.2
-
11
-
-
84893782640
-
IMWG consensus on risk stratification in multiple myeloma
-
Chng WJ, Dispenzieri A, Chim CS, et al; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269-277.
-
(2014)
Leukemia
, vol.28
, Issue.2
, pp. 269-277
-
-
Chng, W.J.1
Dispenzieri, A.2
Chim, C.S.3
-
12
-
-
74049162897
-
International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review
-
Fonseca R, Bergsagel PL, Drach J, et al; International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12):2210-2221.
-
(2009)
Leukemia
, vol.23
, Issue.12
, pp. 2210-2221
-
-
Fonseca, R.1
Bergsagel, P.L.2
Drach, J.3
-
13
-
-
84905842882
-
Best treatment strategies in high-risk multiple myeloma: Navigating a gray area
-
Bianchi G, Richardson PG, Anderson KC. Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014;32(20):2125-2132.
-
(2014)
J Clin Oncol.
, vol.32
, Issue.20
, pp. 2125-2132
-
-
Bianchi, G.1
Richardson, P.G.2
Anderson, K.C.3
-
14
-
-
77950949924
-
Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: Identification of 1p31-32 deletion as a prognostic factor in myeloma
-
Chng WJ, Gertz MA, Chung TH, et al. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. Leukemia. 2010;24(4):833-842.
-
(2010)
Leukemia
, vol.24
, Issue.4
, pp. 833-842
-
-
Chng, W.J.1
Gertz, M.A.2
Chung, T.H.3
-
15
-
-
84055212016
-
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival
-
Boyd KD, Ross FM, Walker BA, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17(24):7776-7784.
-
(2011)
Clin Cancer Res.
, vol.17
, Issue.24
, pp. 7776-7784
-
-
Boyd, K.D.1
Ross, F.M.2
Walker, B.A.3
-
16
-
-
84895803630
-
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: The IFM experience on 1195 patients
-
Hebraud B, Leleu X, Lauwers-Cances V, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2014;28(3):675-679.
-
(2014)
Leukemia
, vol.28
, Issue.3
, pp. 675-679
-
-
Hebraud, B.1
Leleu, X.2
Lauwers-Cances, V.3
-
17
-
-
34548138922
-
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials
-
Moreau P, Attal M, Garban F, et al; SAKK; IFM Group. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia. 2007;21(9):2020-2024.
-
(2007)
Leukemia
, vol.21
, Issue.9
, pp. 2020-2024
-
-
Moreau, P.1
Attal, M.2
Garban, F.3
-
18
-
-
77954477911
-
Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
-
Neben K, Jauch A, Bertsch U, et al. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica. 2010;95(7):1150-1157.
-
(2010)
Haematologica
, vol.95
, Issue.7
, pp. 1150-1157
-
-
Neben, K.1
Jauch, A.2
Bertsch, U.3
-
19
-
-
84875209671
-
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: An International Myeloma Working Group collaborative project
-
Avet-Loiseau H, Durie BG, Cavo M, et al; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013;27(3):711-717.
-
(2013)
Leukemia
, vol.27
, Issue.3
, pp. 711-717
-
-
Avet-Loiseau, H.1
Durie, B.G.2
Cavo, M.3
-
20
-
-
0027164309
-
Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma
-
Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81(12):3382-3387.
-
(1993)
Blood
, vol.81
, Issue.12
, pp. 3382-3387
-
-
Greipp, P.R.1
Lust, J.A.2
O'Fallon, W.M.3
Katzmann, J.A.4
Witzig, T.E.5
Kyle, R.A.6
-
21
-
-
77952903870
-
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie
-
Kapoor P, Fonseca R, Rajkumar SV, et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc. 2010;85(6):532-537.
-
(2010)
Mayo Clin Proc.
, vol.85
, Issue.6
, pp. 532-537
-
-
Kapoor, P.1
Fonseca, R.2
Rajkumar, S.V.3
-
22
-
-
84868559107
-
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
-
Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761-1767.
-
(2012)
Haematologica
, vol.97
, Issue.11
, pp. 1761-1767
-
-
Usmani, S.Z.1
Heuck, C.2
Mitchell, A.3
-
23
-
-
27144493396
-
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
-
Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106(7):2276-2279.
-
(2005)
Blood
, vol.106
, Issue.7
, pp. 2276-2279
-
-
Nowakowski, G.S.1
Witzig, T.E.2
Dingli, D.3
-
24
-
-
84896726037
-
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
-
Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360-364.
-
(2014)
Haematologica
, vol.99
, Issue.2
, pp. 360-364
-
-
Pour, L.1
Sevcikova, S.2
Greslikova, H.3
-
25
-
-
33947217497
-
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
-
Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284.
-
(2007)
Blood
, vol.109
, Issue.6
, pp. 2276-2284
-
-
Shaughnessy, J.D.1
Zhan, F.2
Burington, B.E.3
-
26
-
-
54249092519
-
Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: A study of the Intergroupe Francophone du Myélome
-
Decaux O, Lodé L, Magrangeas F, et al; Intergroupe Francophone du Myélome. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2008;26(29):4798-4805.
-
(2008)
J Clin Oncol.
, vol.26
, Issue.29
, pp. 4798-4805
-
-
Decaux, O.1
Lodé, L.2
Magrangeas, F.3
-
27
-
-
78650981539
-
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
-
Hose D, Rème T, Hielscher T, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2011;96(1):87-95.
-
(2011)
Haematologica
, vol.96
, Issue.1
, pp. 87-95
-
-
Hose, D.1
Rème, T.2
Hielscher, T.3
-
28
-
-
84869085660
-
A gene expression signature for high-risk multiple myeloma
-
Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma. Leukemia. 2012;26(11):2406-2413.
-
(2012)
Leukemia
, vol.26
, Issue.11
, pp. 2406-2413
-
-
Kuiper, R.1
Broyl, A.2
De Knegt, Y.3
-
29
-
-
84926630908
-
Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma
-
Heuck CJ, Qu P, van Rhee F, et al. Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma. Leukemia. 2014;28(12):2410-2413.
-
(2014)
Leukemia
, vol.28
, Issue.12
, pp. 2410-2413
-
-
Heuck, C.J.1
Qu, P.2
Van Rhee, F.3
-
30
-
-
37249040444
-
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
-
Haessler J, Shaughnessy JD Jr., Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007;13(23):7073-7079.
-
(2007)
Clin Cancer Res.
, vol.13
, Issue.23
, pp. 7073-7079
-
-
Haessler, J.1
Shaughnessy, J.D.2
Zhan, F.3
-
31
-
-
84912535316
-
Relapsed and refractory multiple myeloma: New therapeutic strategies
-
Gentili S, Lonial S. Relapsed and refractory multiple myeloma: new therapeutic strategies. Hematol Oncol Clin North Am. 2014;28(5):861-890.
-
(2014)
Hematol Oncol Clin North Am
, vol.28
, Issue.5
, pp. 861-890
-
-
Gentili, S.1
Lonial, S.2
-
32
-
-
54049148621
-
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
-
Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112(8):3115-3121.
-
(2008)
Blood
, vol.112
, Issue.8
, pp. 3115-3121
-
-
Barlogie, B.1
Pineda-Roman, M.2
Van Rhee, F.3
-
33
-
-
84862937267
-
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
-
Morgan GJ, Gregory WM, Davies FE, et al; National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7-15.
-
(2012)
Blood
, vol.119
, Issue.1
, pp. 7-15
-
-
Morgan, G.J.1
Gregory, W.M.2
Davies, F.E.3
-
34
-
-
33845518467
-
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
-
Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21(1):151-157.
-
(2007)
Leukemia
, vol.21
, Issue.1
, pp. 151-157
-
-
Jagannath, S.1
Richardson, P.G.2
Sonneveld, P.3
-
35
-
-
78049488759
-
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial
-
Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28(30):4621-4629.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.30
, pp. 4621-4629
-
-
Harousseau, J.L.1
Attal, M.2
Avet-Loiseau, H.3
-
36
-
-
78049501226
-
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del (17p)
-
Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del (17p). J Clin Oncol. 2010;28(30):4630-4634.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.30
, pp. 4630-4634
-
-
Avet-Loiseau, H.1
Leleu, X.2
Roussel, M.3
-
37
-
-
78650303860
-
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised phase 3 study
-
Cavo M, Tacchetti P, Patriarca F, et al; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-2085.
-
(2010)
Lancet
, vol.376
, Issue.9758
, pp. 2075-2085
-
-
Cavo, M.1
Tacchetti, P.2
Patriarca, F.3
-
38
-
-
77953632707
-
Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
-
Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115(21):4168-4173.
-
(2010)
Blood
, vol.115
, Issue.21
, pp. 4168-4173
-
-
Nair, B.1
Van Rhee, F.2
Shaughnessy, J.D.3
-
39
-
-
84865171981
-
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial
-
Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946-2955.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.24
, pp. 2946-2955
-
-
Sonneveld, P.1
Schmidt-Wolf, I.G.2
Van Der Holt, B.3
-
40
-
-
70149113290
-
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: Adverse effect of deletion 17p13
-
Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114(3):522-525.
-
(2009)
Blood
, vol.114
, Issue.3
, pp. 522-525
-
-
Reece, D.1
Song, K.W.2
Fu, T.3
-
41
-
-
77949423941
-
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
-
Avet-Loiseau H, Soulier J, Fermand JP, et al; IFM and MAG groups. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia. 2010;24(3):623-628.
-
(2010)
Leukemia
, vol.24
, Issue.3
, pp. 623-628
-
-
Avet-Loiseau, H.1
Soulier, J.2
Fermand, J.P.3
-
42
-
-
84860741191
-
Lenalidomide after stem-cell transplantation for multiple myeloma
-
McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.
-
(2012)
N Engl J Med.
, vol.366
, Issue.19
, pp. 1770-1781
-
-
McCarthy, P.L.1
Owzar, K.2
Hofmeister, C.C.3
-
43
-
-
84860709392
-
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma
-
Attal M, Lauwers-Cances V, Marit G, et al; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791.
-
(2012)
N Engl J Med.
, vol.366
, Issue.19
, pp. 1782-1791
-
-
Attal, M.1
Lauwers-Cances, V.2
Marit, G.3
-
44
-
-
84942280436
-
Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients
-
Paper presented at
-
Korde N, Zingone A, Kwok M, et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in newly diagnosed multiple myeloma (MM) patients. Paper presented at Annual Meeting of the American Society of Hematology. November 15, 2013. New Orleans, LA.
-
Annual Meeting of the American Society of Hematology. November 15, 2013. New Orleans, LA
-
-
Korde, N.1
Zingone, A.2
Kwok, M.3
-
45
-
-
84865333050
-
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
-
Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012;120(9):1801-1809.
-
(2012)
Blood
, vol.120
, Issue.9
, pp. 1801-1809
-
-
Jakubowiak, A.J.1
Dytfeld, D.2
Griffith, K.A.3
-
46
-
-
84890429728
-
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
-
Jakubowiak AJ, Siegel DS, Martin T, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013;27(12):2351-2356.
-
(2013)
Leukemia
, vol.27
, Issue.12
, pp. 2351-2356
-
-
Jakubowiak, A.J.1
Siegel, D.S.2
Martin, T.3
-
47
-
-
84884702483
-
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial
-
San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066.
-
(2013)
Lancet Oncol.
, vol.14
, Issue.11
, pp. 1055-1066
-
-
San Miguel, J.1
Weisel, K.2
Moreau, P.3
-
48
-
-
84942280437
-
Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, a phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
-
Paper presented at
-
Dimopoulos M, Weisel K, Song K, et al. Final analysis, cytogenetics, long-term treatment, and long-term survival in MM-003, a phase 3 study comparing pomalidomide + low-dose dexamethasone (POM + LoDEX) vs high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). Paper presented at Annual Meeting of the American Society of Hematology. November 15, 2013. New Orleans, LA.
-
Annual Meeting of the American Society of Hematology. November 15, 2013. New Orleans, LA
-
-
Dimopoulos, M.1
Weisel, K.2
Song, K.3
-
49
-
-
84942280438
-
Pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14)
-
Paper presented at
-
Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14). Paper presented at Annual Meeting of the American Society of Hematology. November 15, 2013. New Orleans, LA.
-
Annual Meeting of the American Society of Hematology. November 15, 2013. New Orleans, LA
-
-
Leleu, X.1
Karlin, L.2
Macro, M.3
-
50
-
-
84893289821
-
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
-
Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123(10):1461-1469.
-
(2014)
Blood
, vol.123
, Issue.10
, pp. 1461-1469
-
-
Richardson, P.G.1
Xie, W.2
Jagannath, S.3
-
51
-
-
84949912218
-
Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma
-
Paper presented at
-
Shah J, Stadtmauer E, Abonour R, et al. Phase I/II dose expansion of a multi-center trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. Paper presented at Annual Meeting of the American Society of Hematology. November 15, 2013. New Orleans, LA.
-
Annual Meeting of the American Society of Hematology. November 15, 2013. New Orleans, LA
-
-
Shah, J.1
Stadtmauer, E.2
Abonour, R.3
-
52
-
-
84902279177
-
Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: An integrated analysis of patient-level data from phase European III studies
-
abstract
-
Cavo M, Salwender H, Rosiñol L, et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies [abstract]. Blood. 2013;122(21). Abstract767.
-
(2013)
Blood
, vol.122
, Issue.21
-
-
Cavo, M.1
Salwender, H.2
Rosiñol, L.3
-
53
-
-
84903939750
-
The graft-versus-myeloma effect: Chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation
-
Donato ML, Siegel DS, Vesole DH, et al. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation. Biol Blood Marrow Transplant. 2014;20(8):1211-1216.
-
(2014)
Biol Blood Marrow Transplant.
, vol.20
, Issue.8
, pp. 1211-1216
-
-
Donato, M.L.1
Siegel, D.S.2
Vesole, D.H.3
-
54
-
-
84904068423
-
Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation
-
Alsina M, Becker PS, Zhong X, et al. Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(8):1183-1189.
-
(2014)
Biol Blood Marrow Transplant.
, vol.20
, Issue.8
, pp. 1183-1189
-
-
Alsina, M.1
Becker, P.S.2
Zhong, X.3
-
55
-
-
82555179157
-
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment trial
-
Krishnan A, Pasquini MC, Logan B, et al; Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12(13):1195-1203.
-
(2011)
Lancet Oncol.
, vol.12
, Issue.13
, pp. 1195-1203
-
-
Krishnan, A.1
Pasquini, M.C.2
Logan, B.3
-
56
-
-
84863520725
-
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
-
quiz 6399
-
Lokhorst HM, van der Holt B, Cornelissen JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 2012;119(26):6219-6225, quiz 6399.
-
(2012)
Blood
, vol.119
, Issue.26
, pp. 6219-6225
-
-
Lokhorst, H.M.1
Van Der Holt, B.2
Cornelissen, J.J.3
-
57
-
-
33646401089
-
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
-
Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474-3480.
-
(2006)
Blood
, vol.107
, Issue.9
, pp. 3474-3480
-
-
Garban, F.1
Attal, M.2
Michallet, M.3
-
58
-
-
84863525019
-
Death of frontline allo-SCT in myeloma
-
Moreau P. Death of frontline allo-SCT in myeloma. Blood. 2012;119(26):6178-6179.
-
(2012)
Blood
, vol.119
, Issue.26
, pp. 6178-6179
-
-
Moreau, P.1
-
59
-
-
65149088043
-
Reduced-intensity allogeneic transplantation for myeloma: Reality bites
-
Stewart AK. Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood. 2009;113(14):3135-3136.
-
(2009)
Blood
, vol.113
, Issue.14
, pp. 3135-3136
-
-
Stewart, A.K.1
-
60
-
-
84907459332
-
Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737
-
Gu D, Wang S, Kuiatse I, et al. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One. 2014;9(9):e103015.
-
(2014)
PLoS One
, vol.9
, Issue.9
-
-
Gu, D.1
Wang, S.2
Kuiatse, I.3
-
61
-
-
77957936826
-
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development
-
Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 2010;18(4):367-381.
-
(2010)
Cancer Cell.
, vol.18
, Issue.4
, pp. 367-381
-
-
Pichiorri, F.1
Suh, S.S.2
Rocci, A.3
-
62
-
-
84878304713
-
MMSET is the key molecular target in t(4;14) myeloma
-
Mirabella F, Wu P, Wardell CP, et al. MMSET is the key molecular target in t(4;14) myeloma. Blood Cancer J. 2013;3:e114.
-
(2013)
Blood Cancer J
, vol.3
, pp. e114
-
-
Mirabella, F.1
Wu, P.2
Wardell, C.P.3
-
63
-
-
78650978001
-
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
-
Martinez-Garcia E, Popovic R, Min DJ, et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011;117(1):211-220.
-
(2011)
Blood
, vol.117
, Issue.1
, pp. 211-220
-
-
Martinez-Garcia, E.1
Popovic, R.2
Min, D.J.3
-
65
-
-
80052269192
-
Monoclonal antibodies in the treatment of multiple myeloma
-
Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011;154(6):745-754.
-
(2011)
Br J Haematol.
, vol.154
, Issue.6
, pp. 745-754
-
-
Richardson, P.G.1
Lonial, S.2
Jakubowiak, A.J.3
Harousseau, J.L.4
Anderson, K.C.5
-
66
-
-
84879563322
-
Genomic instability in multiple myeloma: Mechanisms and therapeutic implications
-
Neri P, Bahlis NJ. Genomic instability in multiple myeloma: mechanisms and therapeutic implications. Expert Opin Biol Ther. 2013;13(suppl 1):S69-S82.
-
(2013)
Expert Opin Biol Ther.
, vol.13
, pp. S69-S82
-
-
Neri, P.1
Bahlis, N.J.2
-
67
-
-
84861532638
-
Clonal competition with alternating dominance in multiple myeloma
-
Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067-1076.
-
(2012)
Blood
, vol.120
, Issue.5
, pp. 1067-1076
-
-
Keats, J.J.1
Chesi, M.2
Egan, J.B.3
-
68
-
-
84877796962
-
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease
-
Egan JB, Kortuem KM, Kurdoglu A, et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol. 2013;161(5):748-751.
-
(2013)
Br J Haematol.
, vol.161
, Issue.5
, pp. 748-751
-
-
Egan, J.B.1
Kortuem, K.M.2
Kurdoglu, A.3
-
69
-
-
41349096886
-
Multiple myeloma presenting with advanced renal failure: A case report and new treatment options
-
Gladney SP, Lonial S, Kaufman JL. Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clin Lymphoma Myeloma. 2008;8(1):52-54.
-
(2008)
Clin Lymphoma Myeloma
, vol.8
, Issue.1
, pp. 52-54
-
-
Gladney, S.P.1
Lonial, S.2
Kaufman, J.L.3
|